Adherence to antiretroviral therapy and viral suppression : analysis of three periods between 2011 and 2017 at an HIV-AIDS center, Brazil
Autor(a) principal: | |
---|---|
Data de Publicação: | 2023 |
Outros Autores: | , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UnB |
Texto Completo: | http://repositorio2.unb.br/jspui/handle/10482/48061 https://doi.org/10.3389/fphar.2023.1122018 |
Resumo: | The increased effectiveness of antiretroviral therapy (ART) in the last 30 years is a scientific landmark, and viral suppression is directly associated with treatment adherence. The aim of this study was to compare the results of ART adherence and viral load suppression with the evolution of the protocols and other associated factors, in people living with HIV. A panel analysis of three descriptive longitudinal studies investigating ART adherence and viral load suppression was conducted in people with HIV treated at a drug dispensing unit in the Federal District. The studies were carried out during periods of 2011, 2013, and 2017, coinciding with the three different recommended treatment schemes for the country. Adherence was assessed using drug dispensing records. Viral load data were obtained from the Ministry of Healthʼs Laboratory Examination Information System. Analysis of the data of 522 individuals in the three periods showed sociodemographic differences such as a decline in the percentage of women (from 33% in period 1 to 4% in period 3) and an increase in the percentage of young people. ART adherence was higher in period 2 (tenofovir/lamivudine/efavirenz scheme). Viral load suppression was greater in period 3 (tenofovir/lamivudine/dolutegravir scheme). The relative detectable viral load risk was nearly two-fold higher (RR 1.83) in people living with HIV with less than 80% adherence when compared to those above 80%. With respect to the different schemes recommended in Brazil during the periods studied, ART containing dolutegravir was the most effective in achieving viral load suppression. By contrast, there was better ART adherence in the daily combined fixed dose consisting of tenofovir/lamivudine/efavirenz in tablet form. Adherence to ART above 80% seemed to be enough to promote an effective treatment in therapeutic schemes including efavirenz or dolutegravir. |
id |
UNB_e111676c4c1f7070bf1a337f9317ba84 |
---|---|
oai_identifier_str |
oai:repositorio.unb.br:10482/48061 |
network_acronym_str |
UNB |
network_name_str |
Repositório Institucional da UnB |
repository_id_str |
|
spelling |
Adherence to antiretroviral therapy and viral suppression : analysis of three periods between 2011 and 2017 at an HIV-AIDS center, BrazilHIV/AIDSAIDS (Doença) - tratamentoTerapia antirretroviralThe increased effectiveness of antiretroviral therapy (ART) in the last 30 years is a scientific landmark, and viral suppression is directly associated with treatment adherence. The aim of this study was to compare the results of ART adherence and viral load suppression with the evolution of the protocols and other associated factors, in people living with HIV. A panel analysis of three descriptive longitudinal studies investigating ART adherence and viral load suppression was conducted in people with HIV treated at a drug dispensing unit in the Federal District. The studies were carried out during periods of 2011, 2013, and 2017, coinciding with the three different recommended treatment schemes for the country. Adherence was assessed using drug dispensing records. Viral load data were obtained from the Ministry of Healthʼs Laboratory Examination Information System. Analysis of the data of 522 individuals in the three periods showed sociodemographic differences such as a decline in the percentage of women (from 33% in period 1 to 4% in period 3) and an increase in the percentage of young people. ART adherence was higher in period 2 (tenofovir/lamivudine/efavirenz scheme). Viral load suppression was greater in period 3 (tenofovir/lamivudine/dolutegravir scheme). The relative detectable viral load risk was nearly two-fold higher (RR 1.83) in people living with HIV with less than 80% adherence when compared to those above 80%. With respect to the different schemes recommended in Brazil during the periods studied, ART containing dolutegravir was the most effective in achieving viral load suppression. By contrast, there was better ART adherence in the daily combined fixed dose consisting of tenofovir/lamivudine/efavirenz in tablet form. Adherence to ART above 80% seemed to be enough to promote an effective treatment in therapeutic schemes including efavirenz or dolutegravir.Faculdade de Medicina (FM)Faculdade UnB Ceilândia (FCE)Curso de Farmácia (FCE-FAR)Programa de Pós-Graduação em Medicina TropicalFrontiersUniversidade de Brasília, Faculdade de Medicina, Programa de Pós-Graduação em Medicina TropicalUniversidade de Brasília, Faculdade de Ceilândia, Curso de Farmácia e Grupo de Pesquisa Acesso a Medicamentos e Uso Responsável (AMUR)Universidade de Brasília, Faculdade de Medicina, Programa de Pós-Graduação em Medicina TropicalUniversidade de Brasília, Faculdade de Medicina, Programa de Pós-Graduação em Medicina TropicalMeiners, Micheline Marie Milward de AzevedoCruz, Igor AraújoToledo, Maria Inês de2024-04-09T16:59:38Z2024-04-09T16:59:38Z2023-03-31info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfMEINERS, Micheline Marie Milward de Azevedo; CRUZ, Igor Araújo; TOLEDO, Maria Inês de. Adherence to antiretroviral therapy and viral suppression: analysis of three periods between 2011 and 2017 at an HIV-AIDS center, Brazil. Frontiers in Pharmacology, [S.l.], v. 14, 31 março 2023. DOI: https://doi.org/10.3389/fphar.2023.1122018. Disponível em: https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1122018/full. Acesso em: 27 março 2024.http://repositorio2.unb.br/jspui/handle/10482/48061https://doi.org/10.3389/fphar.2023.1122018eng© 2023 Milward de Azevedo Meiners, Araújo Cruz and de Toledo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.info:eu-repo/semantics/openAccessreponame:Repositório Institucional da UnBinstname:Universidade de Brasília (UnB)instacron:UNB2024-04-09T16:59:38Zoai:repositorio.unb.br:10482/48061Repositório InstitucionalPUBhttps://repositorio.unb.br/oai/requestrepositorio@unb.bropendoar:2024-04-09T16:59:38Repositório Institucional da UnB - Universidade de Brasília (UnB)false |
dc.title.none.fl_str_mv |
Adherence to antiretroviral therapy and viral suppression : analysis of three periods between 2011 and 2017 at an HIV-AIDS center, Brazil |
title |
Adherence to antiretroviral therapy and viral suppression : analysis of three periods between 2011 and 2017 at an HIV-AIDS center, Brazil |
spellingShingle |
Adherence to antiretroviral therapy and viral suppression : analysis of three periods between 2011 and 2017 at an HIV-AIDS center, Brazil Meiners, Micheline Marie Milward de Azevedo HIV/AIDS AIDS (Doença) - tratamento Terapia antirretroviral |
title_short |
Adherence to antiretroviral therapy and viral suppression : analysis of three periods between 2011 and 2017 at an HIV-AIDS center, Brazil |
title_full |
Adherence to antiretroviral therapy and viral suppression : analysis of three periods between 2011 and 2017 at an HIV-AIDS center, Brazil |
title_fullStr |
Adherence to antiretroviral therapy and viral suppression : analysis of three periods between 2011 and 2017 at an HIV-AIDS center, Brazil |
title_full_unstemmed |
Adherence to antiretroviral therapy and viral suppression : analysis of three periods between 2011 and 2017 at an HIV-AIDS center, Brazil |
title_sort |
Adherence to antiretroviral therapy and viral suppression : analysis of three periods between 2011 and 2017 at an HIV-AIDS center, Brazil |
author |
Meiners, Micheline Marie Milward de Azevedo |
author_facet |
Meiners, Micheline Marie Milward de Azevedo Cruz, Igor Araújo Toledo, Maria Inês de |
author_role |
author |
author2 |
Cruz, Igor Araújo Toledo, Maria Inês de |
author2_role |
author author |
dc.contributor.none.fl_str_mv |
Universidade de Brasília, Faculdade de Medicina, Programa de Pós-Graduação em Medicina Tropical Universidade de Brasília, Faculdade de Ceilândia, Curso de Farmácia e Grupo de Pesquisa Acesso a Medicamentos e Uso Responsável (AMUR) Universidade de Brasília, Faculdade de Medicina, Programa de Pós-Graduação em Medicina Tropical Universidade de Brasília, Faculdade de Medicina, Programa de Pós-Graduação em Medicina Tropical |
dc.contributor.author.fl_str_mv |
Meiners, Micheline Marie Milward de Azevedo Cruz, Igor Araújo Toledo, Maria Inês de |
dc.subject.por.fl_str_mv |
HIV/AIDS AIDS (Doença) - tratamento Terapia antirretroviral |
topic |
HIV/AIDS AIDS (Doença) - tratamento Terapia antirretroviral |
description |
The increased effectiveness of antiretroviral therapy (ART) in the last 30 years is a scientific landmark, and viral suppression is directly associated with treatment adherence. The aim of this study was to compare the results of ART adherence and viral load suppression with the evolution of the protocols and other associated factors, in people living with HIV. A panel analysis of three descriptive longitudinal studies investigating ART adherence and viral load suppression was conducted in people with HIV treated at a drug dispensing unit in the Federal District. The studies were carried out during periods of 2011, 2013, and 2017, coinciding with the three different recommended treatment schemes for the country. Adherence was assessed using drug dispensing records. Viral load data were obtained from the Ministry of Healthʼs Laboratory Examination Information System. Analysis of the data of 522 individuals in the three periods showed sociodemographic differences such as a decline in the percentage of women (from 33% in period 1 to 4% in period 3) and an increase in the percentage of young people. ART adherence was higher in period 2 (tenofovir/lamivudine/efavirenz scheme). Viral load suppression was greater in period 3 (tenofovir/lamivudine/dolutegravir scheme). The relative detectable viral load risk was nearly two-fold higher (RR 1.83) in people living with HIV with less than 80% adherence when compared to those above 80%. With respect to the different schemes recommended in Brazil during the periods studied, ART containing dolutegravir was the most effective in achieving viral load suppression. By contrast, there was better ART adherence in the daily combined fixed dose consisting of tenofovir/lamivudine/efavirenz in tablet form. Adherence to ART above 80% seemed to be enough to promote an effective treatment in therapeutic schemes including efavirenz or dolutegravir. |
publishDate |
2023 |
dc.date.none.fl_str_mv |
2023-03-31 2024-04-09T16:59:38Z 2024-04-09T16:59:38Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
MEINERS, Micheline Marie Milward de Azevedo; CRUZ, Igor Araújo; TOLEDO, Maria Inês de. Adherence to antiretroviral therapy and viral suppression: analysis of three periods between 2011 and 2017 at an HIV-AIDS center, Brazil. Frontiers in Pharmacology, [S.l.], v. 14, 31 março 2023. DOI: https://doi.org/10.3389/fphar.2023.1122018. Disponível em: https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1122018/full. Acesso em: 27 março 2024. http://repositorio2.unb.br/jspui/handle/10482/48061 https://doi.org/10.3389/fphar.2023.1122018 |
identifier_str_mv |
MEINERS, Micheline Marie Milward de Azevedo; CRUZ, Igor Araújo; TOLEDO, Maria Inês de. Adherence to antiretroviral therapy and viral suppression: analysis of three periods between 2011 and 2017 at an HIV-AIDS center, Brazil. Frontiers in Pharmacology, [S.l.], v. 14, 31 março 2023. DOI: https://doi.org/10.3389/fphar.2023.1122018. Disponível em: https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1122018/full. Acesso em: 27 março 2024. |
url |
http://repositorio2.unb.br/jspui/handle/10482/48061 https://doi.org/10.3389/fphar.2023.1122018 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Frontiers |
publisher.none.fl_str_mv |
Frontiers |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UnB instname:Universidade de Brasília (UnB) instacron:UNB |
instname_str |
Universidade de Brasília (UnB) |
instacron_str |
UNB |
institution |
UNB |
reponame_str |
Repositório Institucional da UnB |
collection |
Repositório Institucional da UnB |
repository.name.fl_str_mv |
Repositório Institucional da UnB - Universidade de Brasília (UnB) |
repository.mail.fl_str_mv |
repositorio@unb.br |
_version_ |
1814508220974104576 |